Wave Life Sciences presented disappointing weight loss data by focusing on secondary endpoints (visceral fat) while downplaying its failure on the primary goal of overall weight loss. As the hosts note, this kind of 'hand waving' and non-straightforward data presentation is a major red flag for investors, suggesting the company is hiding bad news.
Wave Life Sciences' drug candidate reduced harmful visceral fat but failed to achieve significant overall body weight loss, a key FDA approval criterion. This outcome suggests that novel mechanisms targeting specific fat types, while scientifically interesting, are commercially unviable if they don't also deliver on the primary endpoint that regulators and patients expect.
Unlike typical pharma M&A where acquired executives depart, Eli Lilly retains and promotes talent from companies it buys, such as Jake Van Narden from Loxo Oncology. This tech-industry style "acqui-hire" strategy helps Lilly absorb entrepreneurial talent and institutional knowledge, embedding innovation directly into its senior leadership ranks.
Instead of competing with established therapies, Allogene is pioneering a "consolidation therapy" niche for its off-the-shelf CAR-T. It is targeting B cell lymphoma patients who are in remission but still test positive for minimal residual disease (MRD)—a high-risk group with an unmet need. This clinical strategy could create an entirely new market.
Terns Pharma successfully shifted its focus after its GLP-1 obesity drug showed underwhelming results. By pivoting to its promising oncology asset for chronic myeloid leukemia, the company dramatically increased its value, culminating in a nearly $7 billion acquisition by Merck. This demonstrates the value of decisively abandoning struggling programs for high-potential ones.
Eli Lilly's deal chief revealed that even premium acquisition offers are frequently rebuffed by public biotech companies without negotiation. This highlights a significant valuation gap where biotech boards believe their assets are worth far more than what even well-capitalized buyers like Lilly are willing to pay, stalling potential M&A activity.